Larimar Therapeutics Submits First Module of Rolling BLA for Nomlabofusp

Larimar Therapeutics has submitted the first module of its rolling BLA to the FDA seeking accelerated approval for nomlabofusp. This submission supports the company's goal for market approval in the rare disease space with positive efficacy and safety data.